Home › Funds › Bain Capital Life Sciences Investors, LLC › NAMS
Bain Capital Life Sciences Investors, LLC position in NAMS
NEWAMSTERDAM PHARMA COMPANY · Health Care
Bain Capital Life Sciences Investors, LLC reported holding 3,806,559 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q3 2026 13F filing — a position valued at US$92.6M, representing 6.37% of its reported portfolio and ranking #5 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed NAMS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Bain Capital Life Sciences Investors, LLC's NAMS position evolved
Bain Capital Life Sciences Investors, LLC first disclosed a stake in NAMS in Q3 2023 at 10,473,913 shares (US$96.9M). The position peaked in Q3 2025 at 10,719,110 shares, worth US$304.9M. Across 13 filings, Bain Capital Life Sciences Investors, LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 3,806,559 shares valued at US$92.6M. Notable position changes include a 32% trim in Q4 2025 (shares fell 9% over the following quarter), a 48% trim in Q2 2026 (shares fell 32% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 10.47M | $96.88M | New |
| Q4 2023 | 10.47M | $116.99M | Hold |
| Q1 2024 | 10.47M | $247.71M | Hold |
| Q2 2024 | 10.47M | $201.20M | Hold |
| Q3 2024 | 10.47M | $173.87M | Hold |
| Q4 2024 | 10.72M | $275.48M | Add |
| Q1 2025 | 10.72M | $219.42M | Hold |
| Q2 2025 | 10.72M | $194.12M | Hold |
| Q3 2025 | 10.72M | $304.85M | Hold |
| Q4 2025 | 7.31M | $256.31M | Reduce |
| Q1 2026 | 7.31M | $233.88M | Hold |
| Q2 2026 | 3.81M | $129.00M | Reduce |
| Q3 2026 | 3.81M | $92.58M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NAMS and 13F data
NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 39 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$206.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NAMS
- Frazier Life Sciences Management, L.P. 18.09M sh · $613.03M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 9.55M sh · $323.66M · Q2 2026
- FCPM III SERVICES B.V. 8.49M sh · $206.49M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.26M sh · $144.53M · Q2 2026
- Maverick Capital 3.27M sh · $110.75M · Q2 2026
- MAVERICK CAPITAL LTD 3.27M sh · $110.75M · Q2 2026
- Duquesne Family Office LLC 3.07M sh · $104.05M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 2.18M sh · $53.07M · Q3 2026
- Castle Hook Partners LP 1.37M sh · $46.46M · Q2 2026
- First Turn Management, LLC 702.40K sh · $17.08M · Q3 2026
- NWI MANAGEMENT LP 702.00K sh · $17.07M · Q3 2026
- Cormorant Asset Management, LP 500.00K sh · $16.95M · Q2 2026
More on Bain Capital Life Sciences Investors, LLC
FAQ
How long has Bain Capital Life Sciences Investors, LLC held NAMS?
Bain Capital Life Sciences Investors, LLC has disclosed NAMS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Bain Capital Life Sciences Investors, LLC's current position in NAMS?
As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 3.81M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $92.58M, representing 6.37% of its reported portfolio and ranking #5.
Has Bain Capital Life Sciences Investors, LLC been buying or selling NAMS?
In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC held unchanged its position in NAMS. The position peaked in Q3 2025 at 10.72M shares.
Which other funds hold NAMS?
Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.